Poster Sessions

Poster Session A
Thursday, February 28: 11:30 AM-1:00 PM and 6:00 PM-7:00 PM

Trials in Progress Poster Session A
Thursday, February 28: 11:30 AM-1:00 PM and 6:00 PM-7:00 PM

Posters by Topic
Combination Studies: Poster Boards A6-B6
Developmental Therapeutics: Poster Boards B7-C8
Implications for Patients and Society: Poster Boards C9-F4
Lung Cancer: Poster Boards A1-A5; F5-H10
Trials in Progress: Poster Boards J1-K1

BOARD A1
Abstract 99: Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial.
First Author: Filiz Oezkan, MD


BOARD A2
Abstract 100: CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.
First Author: Edward Garon, MD, MS


BOARD A3
Abstract 101: Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Daniel Morgensztern, MD


BOARD A4
Abstract 102: Characterizing the T cell repertoire in lung squamous cell premalignancy and its association with lesion outcome.
First Author: Asaf Maoz, MD


BOARD A5
Abstract 103: Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
First Author: Nicolas Guibert, MD, PhD


BOARD A6
Abstract 13: The role of high-dimensional profiling of the systemic immune response on optimal sequencing of radiotherapy (RT) and immune checkpoint blockade (ICB).
First Author: Kevin Chua


BOARD A7
Abstract 14: The outcome and toxicity profile of checkpoint inhibitor immunotherapy subsequent to high-dose IL-2 in the treatment of metastatic melanoma and renal cell carcinoma.
First Author: Stephanie Berg, DO


BOARD A8
Abstract 15: Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
First Author: Matthew Taylor, MD


BOARD A9
Abstract 16: A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.
First Author: Marcia Brose, MD, PhD


BOARD B1
Abstract 17: Evaluating the value of checkpoint inhibitor therapy using the ASCO and ESMO frameworks.
First Author: Sophie Feng, MBBS


BOARD B2
Abstract 18: Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.
First Author: Sant Chawla, MD


BOARD B3
Abstract 19: Managing combination immunotherapy trials from a contract research organization's (CRO's) perspective.
First Author: Jai Balkissoon, MD


BOARD B4
Abstract 20: Low-dose IL-12 preconditions the tumor microenvironment to enhance the efficacy of PD-1 blockade.
First Author: C. Marcela Diaz-Montero, Ph.D.


BOARD B5
Abstract 21: Initial results of a phase III investigation of safety/efficacy of nivolumab and ABI-009 (nab-sirolimus) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS), and Ewing sarcoma.
First Author: Victoria Chua-Alcala, MD


BOARD B6
Abstract 22: The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
First Author: Sant Chawla


BOARD B7
Abstract 28: Automated flow cytometric profiling of tumor heterogeneity, tumor-infiltrating leukocyte (TIL) exhaustion, and coexpression of checkpoint receptors/ligands in patient-derived carcinomas.
First Author: Konstantin Salojin, PhD


BOARD B8
Abstract 29: A phase II single-arm study of CRS-207 with pembrolizumab (pembro) in previously treated malignant pleural mesothelioma (MPM).
First Author: Evan Alley, MD, PhD


BOARD B9
Abstract 30: The effect of adoptive transfer of ex vivo activated T cells on the efficacy and tumor penetrance of intravenously-administered CD3-engaging bispecific antibody.
First Author: Patrick Gedeon, PhD


BOARD B10
Abstract 31: Anti-PD-1 antibody cetrelimab (JNJ-63723283) in patients with advanced cancers: Updated phase I/II study results.
First Author: Piotr Rutkowski, MD, PhD


BOARD C1
Abstract 32: A novel humanized anti-CTLA-4 antibody compared to ipilimumab in preclinical studies.
First Author: Qian Shi, PH.D.


BOARD C2
Abstract 33: Phase I study of cemiplimab, a human monoclonal antibody to programmed death (PD)-1, in Japanese patients (pts) with advanced malignancies: Results from the dose exploration.
First Author: Shigehisa Kitano, MD, PhD


BOARD C3
Abstract 34: Long-term clinical outcomes and transcriptional analysis following partial and complete tumor SBRT plus pembrolizumab.
First Author: Sandeep Bhave, MD


BOARD C4
Abstract 35: PTEN/PI3K signaling in cancer and the response to cytokines: From growth factors to immune actors.
First Author: Sanjay Chandrasekaran, MD


BOARD C5
Abstract 36: Assessment of PD-1 expression in human resting and activated natural killer cells and murine tumor models.
First Author: Sean Judge, MD, MS


BOARD C6
Abstract 37: Localizing radioimmunotherapy via nanochannel device for sustained intratumoral drug delivery for solid tumor treatment.
First Author: Jeremy Ho


BOARD C7
Abstract 38: Optimized intratumoral delivery of a STING agonist results in improvements in local tumor immune activation.
First Author: Rahul Sheth


BOARD C8
Abstract 39: A phase I safety study of oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells.
First Author: Boris Minev, MD


BOARD C9
Abstract 75: Managing immune-related adverse events (irAEs): A new educational resource for health care professionals (HCPs) and patients.
First Author: Laura Wood, MSN, OCN, RN


BOARD D1
Abstract 76: Immune-related adverse event (irAE) education, self-efficacy, and potential irAE experiences in patients treated with immunotherapy for non-small cell lung cancer (NSCLC).
First Author: Urvi Mujumdar, MPH


BOARD D2
Abstract 77: Clinical practice guidelines: Machine learning and natural language processing for automating the rapid identification and annotation of new evidence.
First Author: Craig Whittington


BOARD D3
Abstract 78: Assessing community physician ability to identify and manage immune-mediated adverse events (imAEs) through online continuing medical education (CME).
First Author: Lori Pender, PharmD, MPH, BPharm


BOARD D4
Abstract 79: Expression of T-cell populations and molecular markers of human myocardium with checkpoint-induced myocarditis.
First Author: Abdulrazzak Zarifa, MD


BOARD D5
Abstract 80: A multispecialty approach to immuno-oncology education for community providers.
First Author: Tara Perloff


BOARD D6
Abstract 81: Factors associated with severity of immune checkpoint inhibitor gastroenterocolitis requiring hospitalization in melanoma patients.
First Author: Michael Hughes


BOARD D7
Abstract 82: Real-world characterization of patients with cancer admitted with immune-related adverse events (irAEs).
First Author: Lawson Eng, MD


BOARD D8
Abstract 83: Immune-related adverse events in advanced NSCLC treated with immunotherapy alone or concurrent chemotherapy and immunotherapy.
First Author: John Melson


BOARD D9
Abstract 84: Multisystem immune-related adverse events from anti-PD-1/PD-L1 in patients with lung cancer: Incidence, clinical patterns, management, and outcomes.
First Author: Bairavi Shankar, B.A.


BOARD D10
Abstract 85: Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy.
First Author: RuiQui Chen


BOARD E1
Abstract 86: Prognostic and predictive factors associated with ipilimumab related adverse events: A retrospective analysis of 11 NCI sponsored ipilimumab phase I clinical trials.
First Author: Aman Chauhan, MBBS


BOARD E2
Abstract 87: Identifying obstacles to optimal integration of cancer immunotherapies in the community setting.
First Author: Latha Shivakumar, PhD


BOARD E3
Abstract 88: T-cell lymphoma secondary to checkpoint inhibitor (CPI) used for other malignancies.
First Author: Kartik Anand, MBBS


BOARD E4
Abstract 89: Publication statuses of clinical trials supporting immune checkpoint inhibitors recently approved by the United States Food and Drug Administration: A meta-epidemiological investigation.
First Author: Kenji Omae, MD


BOARD E5
Abstract 90: Patient (pt) experiences with avelumab in treatment-naive metastatic Merkel cell carcinoma (mMCC): Qualitative interview findings from a registrational clinical trial.
First Author: Murtuza Bharmal, PhD


BOARD E6
Abstract 91: Psychosocial distress and access to resources: Preliminary findings from Immunotherapy & Me.
First Author: Maxwell Mulcahy


BOARD E7
Abstract 92: Preliminary study into the impact of immunotherapy on patterns of care and healthcare service utilization in stage IV non-small cell lung cancer in a tertiary hospital setting.
First Author: Xiao Yue Guo, MD


BOARD E8
Abstract 93: Patient reported toxicities: Development and validation of patient-reported symptom measure for lung cancer patients receiving immunotherapy.
First Author: Sandra Shaw, BS, MBA


BOARD E9
Abstract 94: Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy.
First Author: Daniel Spakowicz, PhD, MS


BOARD F1
Abstract 95: Smoking history and PD-1/PDL-1 pathway blockade: Predicting response to treatment in metastatic cancer.
First Author: Caitlin Sullivan, MD, MSc, BSc


BOARD F2
Abstract 96: A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy.
First Author: Joanne Weidhaas, MD, PhD


BOARD F3
Abstract 97: Emotional and cognitive disturbances in long-term melanoma survivors treated with ipilimumab.
First Author: Anne Rogiers, None


BOARD F4
Abstract 98: Planning for survivorship after checkpoint inhibitors: A multidisicplinary education initiative.
First Author: Tara Perloff


BOARD F5
Abstract 104: Outcome, costs and dollar value of anticancer drugs in non-small cell lung cancer with emphasis on pembrolizumab.
First Author: Helmy Guirgis, MD


BOARD F6
Abstract 105: Early shifts in immune cell subsets to predict response to immune checkpoint blockade in non-small cell lung cancer (NSCLC).
First Author: Samuel Rosner, MD


BOARD F7
Abstract 106: Serum NY-ESO-1 and XAGE1 antibodies as predictive biomarkers in anti-PD-1 therapy for non-small-cell lung cancer.
First Author: Mikio Oka, PhD, MD


BOARD F8
Abstract 107: Cancer-immune checkpoint inhibition and autoimmune-related adverse events.
First Author: Joerg Rathmann, MD


BOARD G1
Abstract 108: Nivolumab treatment in advanced non-small cell lung cancer (NSCLC): Retrospective analysis of real-life data in the Hospital Universitario Reina Sofía (HURS).
First Author: Carmen Garcìa Durán


BOARD G2
Abstract 109: Correlation of circulating tumor enumeration and immune checkpoint marker expression on CD103+, CD4+ T cells in non-small cell lung cancer tissue.
First Author: Xiaoyang WANG, PhD


BOARD G3
Abstract 110: Evaluation of PQ500, a 500-plasma protein blood panel in NSCLC subjects using high-throughput MRM mass spectrometry.
First Author: Nicholas Dupuis, PhD


BOARD G4
Abstract 111: Galectins role as predictive markers for anti-PD-1-based immunotherapy in non-small cell lung cancer.
First Author: Carlo Capalbo


BOARD G5
Abstract 112: Preclinical CAR-T cell target safety, biodistribution, and tumor infiltration analysis using in situ hybridization technology.
First Author: Helly Pimentel


BOARD G6
Abstract 113: A severe case of refractory esophageal stenosis induced by nivolumab and responding to personalized treatment.
First Author: Michel Obeid, MD PhD


BOARD G7
Abstract 114: Clinical and molecular characteristics of responders versus non-responders to immune checkpoint inhibitors (ICI) in NSCLC.
First Author: Arpeet Shah, MD


BOARD G8
Abstract 115: Responses to immune checkpoint therapy in pulmonary sarcomatoid carcinoma: A retrospective review.
First Author: Vineeth Sukrithan, MBBS


BOARD G9
Abstract 116: Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from a phase I dose escalation and NSCLC expansion cohort.
First Author: Victor Moreno, MD PhD


BOARD H1
Abstract 117: Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
First Author: Aung Tun, MBBS


BOARD H2
Abstract 118: Immune pneumonitis-related treatment discontinuations and outcomes in metastatic non-small cell lung cancer treated with nivolumab: A pooled analysis from a multi-institutional international collaboration.
First Author: Abdul Naqash, MBBS


BOARD H3
Abstract 119: Outcomes of nivolumab (NIVO)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC) in United States community oncology practice.
First Author: Eric Nadler


BOARD H4
Abstract 120: Estimated costs of grade 3–4 all-cause and treatment-related adverse events for stage IV or recurrent non-small cell lung cancer (NSCLC) in the CheckMate 227 (CM-227) trial.
First Author: David Stenehjem, PharmD


BOARD H5
Abstract 121: Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
First Author: Aung Tun, MBBS


BOARD H6
Abstract 122: Mixed response to immunotherapy in lung cancer.
First Author: Candice Baldeo, MBBS


BOARD H7
Abstract 123: Healthcare provider awareness and integration of immunotherapy for stage III NSCLC.
First Author: Rachael Andrie, PhD


BOARD H8
Abstract 124: Development and correlative analysis of a TML assay in specimens with reference MSI and somatic variant results.
First Author: Hestia Mellert, PhD


BOARD H9
Abstract 125: Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced nonsquamous non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
First Author: Wai Thein, MBBS


BOARD H10
Abstract 126: Phase I study of CpG ODN(K3), a novel toll-like receptor 9 agonist, for advanced lung cancer: Interim analyses of safety and immunity in subcutaneous injection cohort.
First Author: Tomoyuki Otsuka, MD


BOARD J1
Abstract TPS23: Hafnium oxide nanoparticles activated by SABR in combination with PD-1 inhibitors for the treatment of patients with advanced HNSCC or NSCLC: A phase I/II trial.
First Author: Tanguy Seiwert, MD


BOARD J2
Abstract TPS24: Phase I/II dose escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
First Author: William Ho, MD, PhD


BOARD J3
Abstract TPS25: A pilot study of pembrolizumab in combination with decitabine and hypofractionated index lesion radiation in pediatric and young adult patients with relapsed and refractory solid tumors or lymphoma.
First Author: Brian Turpin, DO


BOARD J4
Abstract TPS40: A phase I study evaluating COM701 in patients with advanced solid tumors.
First Author: Drew Rasco, MD


BOARD J5
Abstract TPS41: A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody in advanced cancers.
First Author: Kyriakos Papadopoulos, MD


BOARD J6
Abstract TPS42: FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.
First Author: Michael Millward, MD


BOARD J7
Abstract TPS127: Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).
First Author: Myung-Ju Ahn, MD, PhD


BOARD J8
Abstract TPS128: A phase I trial combining plinabulin and nivolumab for metastatic NSCLC: Trial in progress.
First Author: Nicolas Villanueva, MD


BOARD K1
Abstract TPS129: Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN).
First Author: Elizabeth Ahern, MBBS